biostudies-literatureUnknown52Zambelli AExact Science CorporationGenomic Health Inc<h4>Purpose</h4>Adjuvant treatment decisions in early breast cancer (eBC) have traditionally been driven by risk stratification based on clinical and pathological risk factors. The 21-gene Oncotype DX® assay has been validated as a predictive test for benefit from adjuvant chemotherapy (CT), hence assessing its impact in clinical decisions is of high interest. The objective of this study was to estimate the rate of adjuvant treatment decision modification impacted by the Recurrence Score® result, and the consequent budget impact.<h4>Methods</h4>The study was a multicentre, prospective, real-life experience in Lombardy (Italy) including consecutive patients with T1-T3, N0-N1a, and ER+/HER2-eBC with clinical-pathologic "intermediate risk" of relapse. The change in treatment recommendations wBreast (Edinburgh, Scotland)1-7https://www.ebi.ac.uk/biostudies/studies/S-EPMC7375559biostudies-literatureProspective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.PMC7375559Zambelli AVassalli LFotia VPugliese PLa Verde NCaremoli ERTondini CTorri VColombo GPiacentini GGiordano MPoletti PFarina GSimoncini EfalseProspective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.<h4>Purpose</h4>Adjuvant treatment decisions in early breast cancer (eBC) have traditionally been driven by risk stratification based on clinical and pathological risk factors. The 21-gene Oncotype DX® assay has been validated as a predictive test for benefit from adjuvant chemotherapy (CT), hence assessing its impact in clinical decisions is of high interest. The objective of this study was to estimate the rate of adjuvant treatment decision modification impacted by the Recurrence Score® result, and the consequent budget impact.<h4>Methods</h4>The study was a multicentre, prospective, real-life experience in Lombardy (Italy) including consecutive patients with T1-T3, N0-N1a, and ER+/HER2-eBC with clinical-pathologic "intermediate risk" of relapse. The change in treatment recommendations w2020-01-01T00:00:00Z2020 Aug2025-04-19T11:41:06.4Z2025-04-19T11:41:06.4ZS-EPMC73755593232537210.1016/j.breast.2020.04.003